← Oncology Approval Tracker

FDA DECISION ·

Xtrenbo

denosumab-qbde · Hikma Pharmaceuticals USA

Biosimilar approvalBiosimilarCancer-related skeletal complications and giant cell tumor of bone
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Xgeva biosimilar for preventing skeletal complications in multiple myeloma or solid tumor bone metastases, treating giant cell tumor of bone in eligible adults and skeletally mature adolescents, and treating malignancy-related hypercalcemia refractory to bisphosphonates.

LAMPGEN ANALYSIS

Why it matters

This oncology-dose denosumab approval adds a biosimilar option for the labeled Xgeva uses.

What research teams should watch

Establish a supply transition date and keep visit schedules and medication traceability intact across the change.

PRIMARY RECORDS

Sources